Spectranetics Will Acquire AngioScore

May 27, 2014—Spectranetics Corporation announced that it has entered into a definitive merger agreement to acquire AngioScore, Inc. for $230 million (50/50, cash and stock) plus further payments contingent on commercial and regulatory milestones. The transaction is subject to customary closing conditions. The company expects to close the acquisition on or near June 30, 2014. AngioScore will be a wholly owned subsidiary of Spectranetics.

Spectranetics stated that the transaction will combine two companies committed to solving complex cardiovascular challenges in both the peripheral and coronary markets. AngioScore’s product and distribution platforms will diversify Spectranetics’ portfolio with options to treat critical limb ischemia, in-stent restenosis, calcified lesions, and chronic total occlusions.

AngioScore designs, develops, manufactures, and markets scoring balloon catheters to treat cardiovascular and peripheral artery diseases. The company was founded in 2003 and is based in Fremont, California.

AngioScore’s AngioSculpt technology platform provides a portfolio of solutions to cross, prepare, and treat the coronary and peripheral vasculature. The AngioSculpt RX is a rapid-exchange coronary scoring device. The AngioSculpt PTCA over-the-wire scoring balloon catheter is for the treatment of coronary arteries by percutaneous transluminal coronary angioplasty. AngioSculpt PTA is a scoring balloon catheter for percutaneous transluminal angioplasty treatment of peripheral vascular diseases. AngioScore products are used to treat dilatation of lesions in the iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

Spectranetics develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The company's products treat arterial blockages in the heart and legs and the removal of pacemaker and defibrillator leads.

Spectranetics’ Vascular Intervention products include laser catheters for ablation of blockages in arteries above and below the knee, support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The company also markets aspiration and cardiac laser catheters to treat blockages in the heart. The Spectranetics Lead Management products include excimer laser sheaths, dilator sheaths, mechanical sheaths, and accessories for the removal of pacemaker and defibrillator cardiac leads.